While research has explored birth parent grief and loss, it has not been thorough in exploring how the experience of having an open adoption affects birth parents’ grief and loss experience and resolution. Previous research has highlighted positive effects of open adoptions to date, but is quite limited in regards to the birth parents’ adjustment in current day, open adoptions. This descriptive, qualitative study explores birth parents’ experiences in current day, open adoptions and seeks to understand their experience of grief and loss and their movement towards grief resolution in the context of an open adoption. Findings of this study confirm that the experience of adoption placement involves grief and loss and that openness in adoption helps to mitigate this painful experience. Most notably, birth parents found meaning, comfort, and peace in knowing of their child’s well-being and by having ongoing involvement in the life of the child and adoptive family. This opens new avenues in thinking about adoption and the meanings participants make of it.Même si la recherche s’est penchée sur le deuil et la peine des parents biologiques, elle n’a pas approfondi l’effet d’une adoption ouverte sur leur douleur et leurs façons de composer avec celle-ci. Des recherches ont montré les effets positifs de l’adoption ouverte, mais elles ont peu abordé l’adaptation dont doivent faire preuve les parents biologiques ayant choisi l’adoption ouverte de nos jours. La présente étude descriptive et qualitative explore l’expérience vécue par les parents biologiques et cherche à comprendre leur deuil et leur peine ainsi que leurs façons de les surmonter. Les résultats montrent que la décision de confier un enfant à l’adoption s’accompagne d’un deuil et d’une peine, et qu’une ouverture permet d’atténuer la douleur d’une telle action. En particulier, les parents biologiques ont trouvé un réconfort à être au courant du bien-être de leur enfant et à garder contact avec celui-ci et sa famille adoptive. Cette étude ouvre de nouvelles perspectives au sujet de l’adoption et du sens que les participants lui donnent

The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. LNCaP cells were treated with valproate, temsirolimus or a combination of both. The proliferation rates and the expression of key markers of tumorigenesis were evaluated. In in vivo experiments, LNCaP cells were implanted into immune-suppressed male nude mice. Mice were treated with valproate (per os), temsirolimus (intravenously) or with a combination of both. Tumor volumes were calculated and mRNA expression was quantified. The incubation of LNCaP cells with the combination of valproate and temsirolimus resulted in a decrease of cell proliferation with an additive effect of both drugs in comparison to the single treatment. In particular, the combined application of valproate and temsirolimus led to a significant upregulation of insulin-like growth factor-binding protein-3 (IGFBP-3), which mediates apoptosis and inhibits tumor cell proliferation. In the mouse model, we found no significant differences in tumor growth between the different treatment arms but immunohistological analyses showed that tumors treated with a combination of valproate and temsirolimus, but not with the single drugs alone, exhibited a significant lower proliferation capacity.